UK markets closed
NIKKEI 225
38,179.46 -49.65 (-0.13%) HANG SENG
19,115.06 +151.38 (+0.80%) CRUDE OIL
79.15 +0.89 (+1.14%) GOLD FUTURES
2,343.50 -31.50 (-1.33%) DOW
39,452.34 -60.50 (-0.15%) Bitcoin GBP
50,169.16 +1,324.77 (+2.71%)
GILD Jun 2024 80.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:43PM EDT. Market open.
| Previous close | 0.0700 |
| Open | 0.1100 |
| Bid | 0.0200 |
| Ask | 0.0700 |
| Strike | 80.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.0400 - 0.1100 |
| Contract range | N/A |
| Volume | |
| Open interest | 4.22k |
Yahoo FinanceOne stock is dragging down the S&P 500's earnings growth
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
ZacksGilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Business WireKite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
REDWOOD CITY, Calif. & SANTA MONICA, Calif., May 09, 2024--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
© 2024 Yahoo. All rights reserved.